Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

54.14 -0.57 (-1.04%)
Official Closing Price Updated: 4:10 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
65 66 Next >
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
One offers more income today, and the other aims to offer more in the future. 
Via The Motley Fool
Should Income Investors Buy This Blue Chip Dividend Stock?
This pharmaceutical company has an exceptional drug portfolio and pipeline. 
Via The Motley Fool
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:NNOX),(NASDAQ:SNGX),(NASDAQ:CRDF) EQNX::TICKER_END 
Via FinancialNewsMedia
Bristol-Myers Squibb Earnings Perspective: Return On Capital Employed
Via Benzinga
Bristol-Myers Squibb Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Insiders Selling Zoom Video Communications, Bristol-Myers Squibb And This Footwear Manufacturer
The Nasdaq closed lower on Thursday after the Fed increased rates by 25 basis points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
7 Best Dividend Stocks to Buy Now in May 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. 
Via The Motley Fool
Want Passive Income at a Fair Price? Consider Buying This Dividend Growth Stock
It's in the sweet spot for the right kind of investor. 
Via The Motley Fool
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
From Bristol Myers Squibb
Via Business Wire
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers 
Via MarketBeat
Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Bristol-Myers Squibb Co (NYSE: BMY) announced  
Via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) Highlighted for Surprising Price Action
Via Investor Brand Network
Exposures COVID-19
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
From Bristol Myers Squibb
Via Business Wire
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol Myers Squibb Posts Lower Q1 Sales As Revlimid Generic Erosion Bites, Chairman & CEO Giovanni Caforio To Step Down
Via Benzinga
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Leadership Transition Plan
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
From Bristol Myers Squibb
Via Business Wire
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients
LianBio (NASDAQ: LIAN) announced  
Via Benzinga
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market – Interim Results Could Be Released In Second Half Of 2023
Recently, Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clini 
Via Benzinga
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
From Bristol Myers Squibb
Via Business Wire
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.